Abstract There is a growing appetite for large complex databases that integrate a range of personal, socio-demographic, health, genetic and financial information on individuals.
personalised or targeted therapies [1] . In a recent Lancet Oncology Commission paper, Sullivan and colleagues [2] discuss many of the challenges of delivering affordable cancer care in the future, highlight the drivers of health costs and provide a number of potential remedies so countries can continue to deliver high-quality care to all cancer patients in an affordable way. An overriding theme of the 'solutions' is the need for more research, in order to ensure evidence-based practice and policy.
'Big Data' provides one vehicle within which to undertake this research [3] , particularly with the growth of electronic health records [4] . Big Data has been described as the increasing capacity of information systems to collect and store large volumes of unstructured data that are difficult to process in standard relational databases [5, 6] . As the amount of data being collected electronically grows, and the ability to undertake data linkage across databases increases, there will be more and more complex datasets in the health domain that will be considered Big Data. Such databases would bring together personal, socio-demographic and health outcomes data on individuals with records of their health resource use and expenditure data. The inclusion of rich clinical information such as genomic data, particularly in the field of cancer research, would additionally increase the usefulness of Big Data as genomics is now pivotal to both clinical care and advancing the science of medicine.
There are a number of datasets that could be described as Big Data, but many of these stem from individual/household/health surveys; thus, few include clinical data, and even fewer are linked to healthcare records. The Midspan studies, an early example of Big Data, are surveys undertaken in the 1960s that have over 40 years of followup as a result of longitudinal linkage to health records (via the Scottish Morbidity Records [SMR] ) and the death registry (see Hart et al. [7] and Geue et al. [8] ). Specifically in cancer, cancer registries provide a useful starting point for Big Data, and the most comprehensive to date is the National Cancer Institute's (NCI) Surveillance, Epidemiological, and End Results (SEER) programme, which pools data from 18 cancer registries in the USA, dating back to 1973. It has built on the registry data by establishing a linkage with Medicare (SEER-Medicare) and also has a linkage to outcomes data via the Medicare Health Outcomes Survey (SEER-MHOS).
In Victoria, Australia we have designed Cancer 2015, a prospective, longitudinal, genomic cohort study, which we hope will rival SEER and many other cancer cohorts. [9] Cancer 2015 seeks to trace the entire cancer journey from diagnosis to treatment and management, to death. Its purpose is to evaluate and then implement a new model of cancer diagnosis and treatment, with a specific focus on integrating molecular pathology into routine cancer diagnosis. Recruitment has been ongoing since November 2011 and involves five Victorian hospitals: two capital city public hospitals, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital; a city private hospital, Cabrini Hospital; a non-capital metropolitan public hospital, Geelong Hospital (Barwon Health); and a regional public hospital, Warrnambool Hospital (SouthWest Health). Phase 1 sought to recruit 1000 newly diagnosed (treatmentnaïve) cancer patients; Phase 2 is ongoing and recruitment as of May 2015 is in excess of 1600 patients. Ultimately, it aims to enrol [10,000 patients. Patients consent to have their tumour biopsy and blood screened using next-generation sequencing (NGS). A baseline questionnaire collects information on patient socio-demographics and patient and familial history. Clinical records including pathology results are drawn upon to gather information on tumour site and stage and treatment intentions (including changing intentions over time). Patients are also asked to complete quality-of-life (QOL) questionnaires (EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life. Questionnaire-C30 [EORTC QLQ-C30]) at baseline, which are repeated at 6 and 12 months follow-up (or 3 months for those with advanced disease).
At enrolment, patients are requested to additionally consent to have their Commonwealth (pharmaceutical and medical services) and State (hospital admissions and presentations) reimbursement data linked. It is this linkage that creates what we believe is the most comprehensive database in existence today, which will, with increasing enrolment, create Big Data. While SEER has breadth that would be difficult to compete with given both its coverage and the population of the USA, it can lack generalisability because its resource use records are restricted to Medicare beneficiaries (which for breast and colorectal patients is less than half of all patients [10] ), while the outcomes data are collected for a random sample only, with limited follow-up (assessed at diagnosis and 2 years later), and do not appear to be linked to the resource use data. Furthermore, it has limited information on biomarkers (see Reichman et al. [11] ). In comparison, Cancer 2015 has considerable depth of data.
It is hoped that Cancer 2015 can set a precedent for the growing number of genomic cohorts that are being established; while it is likely that these, particularly Genomic England's 100,000 Genome Project, will surpass Cancer 2015 in both depth and breadth, Cancer 2015 can offer early learnings. This paper offers insight to other researchers by describing the process of creating Big Data with both genomic and economic information and the linkage of a genomic cancer cohort to healthcare reimbursement data (providing both volume and variety). 1 It discusses many of the challenges that are involved given the multiple stakeholders and data access issues (offering insights on velocity, veracity and validity). The paper culminates with an estimation of the determinants of the cost of cancer; this application provides an example (or case study) of some of the issues with data heterogeneity and data analytics (i.e. variability) that arise when analysing Big Data using standard econometric approaches, but nonetheless provides a greater understanding of which patient, disease, genomic and treatment characteristics explain the variation in health expenditure (i.e. the value of Big Data).
Cancer 2015 Data Linkage
The Commonwealth and State reimbursement databases in Australia are relatively comprehensive (possibly due to the complexity and the need for accountability in a two-tier mixed system), and are reasonably accessible. The Cancer 2015 data custodian sends DHS copies of these consent forms, and they extract data based on the Medicare number. These data are then forwarded to the research team, and are linked with the cohort data and the plethora of genomic panel results [17] (see Sect. 7; Fig. 3 ). This master database is available for all researchers to utilise; 4 however, it only provides a partial picture of health expenditure as it does not include any secondary care (hospitalisation or outpatient) resource use.
The last stage of linkage is with the State hospitalisation data. For legislative reasons, the Victorian Data Linkage (VDL) Unit, in the Victorian Department of Health and Human Services (DHHS), undertake this last linkage in-house. The data custodian sends VDL the master database, and VDL establishes a linkage to hospital admissions in the Victorian Admitted Episodes Database (VAED) and emergency department presentations in the Victorian Emergency Minimum Database (VEMD) by using a combination of identifiers, including hospital unique record numbers, partial Medicare number, partial first names, date of birth, sex, postcode and country of birth [18] . All identifiers are removed before VDL returns the de-identified master database and the VAED and VEMD datasets with a linkage key to the health economics chief investigator (PKL). To further protect patient privacy, all dates (including study dates, e.g. consent date; dates of prescribing from the PBS and dates of service provision in the MBS; dates of admission and presentations) are coded only to the month-year. If we wish to undertake analyses to understand pathways of care, such as to explore the order of medical services, treatments and hospitalisations within the same month, then further interaction with VDL is required so they can create encrypted dates to enable the sequencing of dates. An additional anonymity feature is that the treating hospital within the VAED and VEMD data is not identifiable; while it is possible to see whether patients are using different hospital providers, who these providers are and their geographical relationship to the patients' residence is unknown, although VDL can create variables to reflect such distances and relationships.
One outstanding issue that is less likely to be resolved is the lack of contemporaneous data (so-called data velocity, where data are available and processed in real time [12] ). Due to the reimbursement of service providers, DHS only provide data for a period up to 3 months prior the request date, e.g. PBS/MBS data requested in February 2014 are complete up to November 2013. Once returned (DHS work on a turnaround of about 3 months), these data are cleaned, coded and merged with the cohort and genomic panel data to create the master database. The master database is then uploaded to VDL; VDL then undertake their database extraction and de-identify the cohort data, as a minimum, within 8 weeks. This process results in the final data that are returned to the health economics team being at least 8 months out of date. A final issue with this linkage arrangement is an inability to update the data; because the data returned to the health economics team are de-identified, any updates require that it be sent back to VDL for relinkage and de-identification again. This means adding information on survival/deaths or new NGS panel results (if a biopsy is repeated or blood taken) cannot be done readily.
These issues aside, the linkage of Cancer 2015 with Commonwealth and State resource use and reimbursement 2 MBS data will also capture private hospital services and hospital outpatient services if they are billed via Medicare. 3 As the cohort did not specifically target the elderly, and is not expressly interested in issues with end-of-life care, we chose not to establish a linkage with the Commonwealth Department of Veterans' Affairs (DVA) database. Furthermore, the cost of requesting Commonwealth data is not inconsequential, so it was also for budgetary reasons. This likely means that our estimate of total healthcare expenditure is an underestimate. See Ward et al. [16] for an analysis that includes DVA patients. 4 Interested researchers are invited to discuss applications to access the Cancer 2015 data with the Steering Committee. data has resulted in what we believe is the most comprehensive database in existence today; one that includes information on clinical, genomic, QOL and resource use records for a group of newly diagnosed cancer patients over time. An added benefit is that all patients consent to their (MBS/PBS) data being collected from the start of the study (November 2011) and not from their enrolment into the study, meaning we have a history of resource use prediagnosis. 5 See the Electronic Supplementary Material for an example and description of a composite patient's case history (composite to avoid possible identification of actual patients in the dataset, in accordance with the DHHS Conditions of Release).
Data
At February 2014 there were 1119 patients recruited to Cancer 2015. The details of patients who consented to PBS and/or MBS record retrieval were sent to DHS, and in June 2014 we received data on 987 patients with PBS records and 1093 patients with MBS records for the period from November 2011 to November 2013 (note that some patients, despite consenting, did not appear in either the PBS or MBS records; this may be because they did not have a Medicare number, i.e. they aren't eligible, or an incorrect Medicare number was recorded, or there were mistakes in the prescribing/provision data with regard to their Medicare number so linkage was not possible). The PBS/MBS data were merged with updated cohort data and the genomic data 6 as of June 2014 and a dataset with 1480 patients were uploaded to the VDL (note that the cohort continues to recruit patients, thus to maximise the data we added new enrollees since February 2014, acknowledging that for some of these we have not yet procured their PBS/ MBS data). In January 2015, the VDL returned the deidentified cohort data and VAED records for 1323 patients and VEMD records for 790 patients for the period from June 2010 to June 2014; the datasets were linked using the linkage key. 7 To provide an estimate of the total monthly cost of cancer care, the primary and secondary care costs (including known out-of-pocket expenditure) were aggregated. The PBS and MBS datasets include information on the government benefit paid and the patient out-of-pocket costs, but the admissions and presentations data required valuation. The hospital admissions records include a weighted inlier equivalent separation (WIES) for each admission. This is a cost weight that is adjusted for time spent in hospital and represents a relative measure of resource use for each episode of care in a diagnostic resource group (DRG). To estimate the cost of an admission the WIES was multiplied by the National Efficient Price (NEP) for each year [19] . Private hospitals (and private admissions in public hospitals) were estimated to cost 0.82 of a public hospital episode, which reflects the fact that in-hospital services and pharmaceuticals for private patients are covered by Medicare (so are in the MBS) and the PBS, respectively. The cost of emergency presentations was estimated by weighting the average cost of a presentation by the triage category and departure status of the patient [20] .
In order to understand the variation in total health expenditure, we constrained the time period to between November 2011 and October 2013 (where there is data overlap), and only included those individuals with MBS and PBS activity at some time during this period. 8 The data are organised in a panel fashion, such that a patient appears multiple times in the data, with each row corresponding to a month; patients who died have their data truncated. Summary statistics of average monthly expenditure preand post-diagnosis are given in Table 1 , together with average monthly resource use. Average monthly health expenditure (and resource use) was significantly higher post-diagnosis (p \ 0.001). This relationship is apparent in the plot of monthly expenditure over time (see Fig. 1 ). There is a large spike in health costs just after diagnosis; notably, this trend for higher cost remains for some time post-diagnosis. 9 The trend just after diagnosis is also evident when considering specific sites of cancer. Figure 2 plots the average monthly cost post-diagnosis for four headline cancers.
While this is an incredibly rich dataset, its data properties do bring challenges that are often overlooked when researchers advocate for Big Data. Notably, the cost data are skewed, although this is not uncommon with expenditure data [21] ; however, of more relevance is the high proportion of zeros. Pre-diagnosis, these individuals are seemingly healthy, and as such nearly 30 % of all monthly expenditures are zero. Post-diagnosis 12 % of the monthly expenditures are zero; i.e. records show no resource use in the month, and therefore incur no cost. For simplicity, we avoid issues associated with handling excess zeros in our data [22] and focus only on the post-diagnosis costs. Additionally, we collapse the data such that rather than it being monthly, it is instead bi-monthly (i.e. each row is a summation of 2 months of expenditure); as a result, only 5.3 % of bi-monthly health expenditure estimates are zero. In total, we have a sample of 922 patients, with 5573 observations, where an individual patient Part of the uniqueness of this database is the wealth of genomic data. The panel produces information on 212 amplicons from 48 genes that are known mutational hotspots in genomes of a wide variety of different tumour types [23] . Data on the frequency of an identified mutation, type of gene where a mutation occurs (e.g. oncogene or tumour suppressor gene), the pathway the gene is involved in (e.g. cell cycle/apoptosis, DNA damage control, RAS, PI3K), the consequence of the mutation (e.g. missense, frameshift, stop-gain) and the pathogenicity classification of the mutation are collected. However, we focus on only a few of these genomic characteristics in this case study. Note that the sample for this subsequent analysis is smaller as a quality-control filter was applied to NGS samples to set thresholds for variant analysis; as such, we are restricted to a sample where genomic data are of high quality (n = 621) [17] . This changes the sample somewhat as inclusion is dependent on there being enough tissue (DNA of sufficient quantity for sequencing) with sufficient read coverage; note that the results for the analysis with this smaller sample are similar to those for the full sample.
Estimation Methods
To determine the drivers of individual bi-monthly health expenditure, we exploit the panel nature of our data and estimate a fixed-effects equation of the form (Eq. 1):
where y it is health expenditure of individual i in time period t post-diagnosis, a i contains individual-specific, time-invariant (fixed) effects, x it is a vector of time-varying covariates (such as information on resource use), k t is a time trend and e it is an error term. 10 For k t , we experimented with various polynomial specifications and a series of spline variables to allow for a flexible functional form; our preferred specification according to both the Akaike and Bayesian Information Criterion (AIC and BIC) is a third-order polynomial. Given the skewed nature of the data, a variety of alternate specifications were examined, including log-transformation models (with homogeneous and heterogeneous smearing) and generalised linear models (GLMs) with gamma and negative binomial distributions. In all circumstances the root mean squared error and mean absolute error for in-sample forecasts were lowest under the linear specification. As we are interested in the individual-specific time-invariant effects, we follow Ellis et al. [24] and recover these estimates by modelling them as a linear function of timeinvariant covariates, z i , in a second-stage regression (Eq. 2):
where z i includes demographic information and variables collected at baseline only, and u i is an error term. The covariates included in the fixed-effects equation that varied bi-monthly (x it ) were a dummy variable for whether any admissions were private; a dummy variable for whether any admissions were day case; a dummy variable for whether a general practitioner (GP) was consulted; a dummy variable for whether an oncologist was consulted; dummy variables for whether they were prescribed medications for digestion or anxiety/depression; 11 a dummy for whether they received a targeted/stratified drug; a dummy for whether they were tested for a genomic mutation as part of standard care; a dummy for whether palliative care was indicated; QOL as measured by the EQ-5D-3L; 12 and a variable to reflect time trend (and its square and cube). These variables were included to reflect changing treatment patterns and health status over time; the 11 These were identified in the PBS records using the high level ATC (Anatomical Therapeutic Chemical) Code. These two ATC codes were included to reflect possible adverse effects of cancer treatment. 12 The UK EQ-5D-3L values were used to estimate EQ-5D values. We used a means of forward (and backward) extrapolation to determine QOL prior to (after) the first (last) recorded EQ-5D-3L, and a method of linear interpolation between QOL measurement points, such that we have a measure of QOL for each time period.
time trend and its polynomials were included to allow for possible non-linearities in total cost over time. The covariates that were time invariant (z i ) and were included in the residual second-stage regression included site of cancer; stage of cancer; whether the patient died; sex; age group; recruiting hospital; Eastern Cooperative Oncology Group (ECOG) performance status; whether the patient had hospital cover; smoking status; means of presentation (symptomatically or not); treatment intention; history of cancer; and the Charlson Comorbidity Index. In the subgroup regression analysis focusing just on patients with (high-quality) genomic data, additionally included in the z i values was whether a patient had an actionable mutation; the number of variants found; and nine specific genomic variants (see the last panel in Table 2 for more detail). We include specific information on mutations in the model, not simply because we have the data available, but because such biomarkers can be indicative of more aggressive tumours, which would make them more costly to treat. The cost of the NGS is not included in the calculations of total cost as currently this information is not provided to the practicing clinicians, and therefore does not inform any treatment decisions. All targeted therapies prescribed on the PBS have an accompanying MBS reimbursed test (as co-dependents). In Phase 2 of Cancer 2015 we will be undertaking real-time reporting of the genomic information, i.e. sending this information to clinicians. Note that we have scaled the dependent variable, so that it is expenditure/1000, given the large magnitude of some of the values. 13 
Results
The panel regression results are given in Table 3 for the full sample and the sub-sample with sequenced data. Due to space constraints, only a few of the statistically significant relationships are discussed below. Private admissions, consults with oncologists and experiencing possible cancer treatment adverse effects all have a positive effect on bimonthly health expenditure; for example, having a private admission during the bi-monthly period increases bimonthly expenditure by 9500 Australian dollars ($A) (2012-2013 prices). The covariate with the largest magnitude is whether a patient received a targeted drug; this increases bi-monthly expenditure by $A12,060. This is not unexpected, however, as monthly courses of many targeted therapies (trastuzumab, imatinib, gefitinib and sorafenib) have published prices of above $A4000 per month, and will require monitoring, which comes at additional cost. Notably, consulting with a GP reduces bi-monthly expenditure, perhaps because this happens outside of cancer treatment phases; palliative care also reduces expenditure. The negative effect of palliative care is likely to be due to these patients leaving the acute care setting and moving to hospice accommodation, information on which is not currently available at the State level. Having higher health-related QOL (HR-QOL), as measured by the EQ-5D-3L, also decreases total health expenditure. The (linear) time trend variable is statistically significant and negative, which suggests that as patients progress bi-monthly costs decline; this trend is evident in Fig. 1 .
In terms of site of cancer, prostate, lung, head and neck, colorectal, bone and soft tissue, oesophagogastric, renal, ovarian, cervical, bladder, pancreatic and other sites incur more expenditure than breast cancer. Stage is statistically significant, although it should be noted that it is difficult to compare stages across cancer sites. Table 2 shows that those patients who are deceased and male are more expensive, and the younger the patient the increasingly greater the costs of care. Interestingly, all hospital sites are more expensive than Peter Mac, the speciality cancer hospital in the state.
The impact of the genomic variables on bi-monthly health expenditure is difficult to interpret from Phase 1 of the Cancer 2015 cohort. As discussed in Sect. 4, during Phase 1 the genomic panel data are not being utilised to alter care and/or treatment decisions for the enrolled patients. In Phase 2 this information will be reported to treating clinicians, and thus will likely change clinical care, healthcare resource use and health expenditure. Given this, we attempt to hypothesise why the effects we have found might exist.
The presence of well-known driver mutations seems to have differential effects on health expenditure. Patients harbouring a variant in either TP53 or KRAS showed higher expenditures, whereas those harbouring variants in either ERBB2 or PIK3CA had lower expenditures. Patients with KRAS mutations, specifically those diagnosed with colorectal cancer, are unable to receive first-line treatment with the targeted agent cetuximab (only available to patients with KRAS wild-type metastatic colorectal cancer) and therefore may receive treatment with other expensive targeted agents such as bevacizumab, or progress more rapidly due to limited effective treatment options, potentially resulting in higher expenditures. Patients with ERBB2 mutations, specifically those diagnosed with advanced breast cancer, would be candidates to receive the targeted therapy trastuzumab, but prior to May 2015 this was prescribed outside of the PBS (in the Herceptin Program, see Sect. 6) and as such the cost of this expensive therapy 13 All analyses were undertaken in STATA/MP Ò 13 (STATACorp LP, College Station, TX, USA). The dataset required manipulation and selection to perform optimally; it is likely that future analyses with more linked data will require alternate software packages. 
Discussion
Big Data offers considerable promise, especially in the domain of cancer research. The SEER data have to date provided one of only a few sources of quality data that give a population perspective to cancer incidence, prevalence and clinical outcomes, and its linkages to Medicare and HR-QOL data have further enhanced its value [25] . However, cancer research is now increasingly focused on genomics and there is a need for contemporaneous and high-quality data that includes information on mutations and biomarkers. Cancer 2015 is one of the first comprehensive cohort studies to address this evidence gap, with data including patient demographics and clinical treatment decisions, to QOL outcomes and NGS genomic data. While it is already rich with data, it has been additionally enhanced by establishing linkages to Commonwealth and State reimbursement data, to create the premise of Big Data (Big Data that will continue to grow in size with greater enrolment in the cohort and longer follow-up). Here we offer just one example of the value of the data, seeking to explain health expenditure, but additional analyses of the linked dataset will offer up answers to such questions as what is the (inter-)relationship between the components of health expenditure, are they substitutes or complements [26] ?; what is the relationship between QOL and cost over time?; and what role does genomics play in delivering costeffective care? However, it is important to acknowledge the limitations of this type of data, particularly data whose function is for reimbursement or audit and not research. Equally, when building these data it is important to respect the agencies involved; their purpose is generally not to facilitate research. It is necessary to recognise the time delays also, and the intricacies of the system. For example, trastuzumab for advanced breast cancer has only just received approval to be listed on the PBS (note that it has been listed on the PBS for early-stage breast cancer since 2006), as it was not cost effective when first evaluated, and was instead listed with its own programme, the Herceptin Program, in 2001. When managing patient consent protocols this was overlooked, and as such we are unable to access this information for the Phase 1 patients (note in Phase 2 we are now consenting for it).
The size of Big Data can also be a limitation. In the face of large amounts of data (particularly when there is a lot of information on each individual), standard modelling approaches often give way to machine learning and other data-mining approaches such as classification and regression trees (CART). Such data-mining techniques have been shown to produce useful prognosis and prediction models [27, 28] , but it is important to understand the complexities of the data and make appropriate inferences [29] . SEER provides an example of this: the NCI recently announced that it has removed all prostate-specific antigen (PSA) data from SEER after questions arose regarding the accuracy of PSA values and possible misinterpretation [30] . Additionally, more of the same data (e.g. more claims data) will not reduce bias when what is required are different data (e.g. data on clinical stage), although data linkage can address this problem [29] . Note also that the performance of CART and other data-mining techniques in the presence of a large number of zeros, as will often be the case with healthcare resource use and expenditure data, is currently unknown.
Large linked databases are becoming commonplace, with many countries having national centralised databases of health records and personal information for entire cohorts [31] . It is important moving forward that we begin to harness the power of these datasets. They will increase our ability to minimise uncertainty with large sample sizes, across a range of variables, allowing us to test new theories and relationships, all of which will help inform future health policy and practice, allowing the delivery of healthcare within budget for maximum effect. 
